About ALK-Abelló
Undoubtedly, allergy is considered the epidemic of the 21st century. The number of allergy sufferers is increasing dramatically from year to year. In Austria already about 25 percent of the population react allergic.
ALK-Abelló counters this development with specific immunotherapy (SIT) or allergy vaccination for the treatment of allergic rhinitis, allergic asthma and insect venom allergies.
With the development and distribution of specific and molecularly defined allergens for diagnosis, treatment and prevention, ALK research set globally recognized standards, allowing ALK-Abelló to quickly become the market leader.
ALK-Abelló has been present in Austria since 1978, with its headquarters in Linz. Production, research and development are carried out in Spain (Madrid) and Denmark (Horsholm).
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of company presentation. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
- Industry : Pharma
